Have any thoughts about
Seagen Inc?
Write Note

P/E
Price to Earnings

-56.8
Current
-53.3
Median
23.3
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-56.8
=
Market Cap
39.3B EUR
/
Net Income
-750.2m USD
All Countries
Close
Earnings Growth
US
S
Seagen Inc
F:SGT
Average P/E: 56.8
Negative Multiple: -56.8
N/A
US
Abbvie Inc
NYSE:ABBV
62.9
406%
US
Amgen Inc
NASDAQ:AMGN
55.1
74%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -262.7
38%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
25.7
56%
US
Gilead Sciences Inc
NASDAQ:GILD
103.4
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -490.7 N/A
AU
CSL Ltd
ASX:CSL
36.8
64%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -521.2 N/A
KY
Beigene Ltd
SSE:688235
Negative Multiple: -57.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -127.2 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-53.2
2-Years Forward
P/E
-112.3
3-Years Forward
P/E
363

See Also

Discover More